Switzerland Archives

News and Trends 10 Apr 2017

Swiss-Danish Collaboration will use Synbio to Produce a B Vitamin

Two startups in the fields of synthetic biology, Biosyntia and FGen, have struck a partnership to identify promising microbial strains. The objective is to find a strain that enables bioproduction of a B vitamin. The driving force of this new partnership between Biosyntia, Denmark, and ETH Zurich, and brands itself as a CRO for biologics […]

April 10, 2017 - 2 minutesmins - By Denise Neves Gameiro

Numab Ono Pharmaceutical Immuno Oncology

News and Trends 28 Mar 2017

Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster

Ono Pharmaceutical is offering the Swiss Numab €241M (CHF 258M) for the development of a multi-specific antibody for immuno-oncology applications. Numab, one of the hottest biotechs in Zurich, has developed a unique technology to generate stable antibody fragments (not an easy feat!) and use them as building blocks for multi-specific antibodies that can target up […]

March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Mar 2017

Novartis puts the Development of two Anti-Aging Drugs in American Hands

PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […]

March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 20 Mar 2017

UPDATE: Swiss Medtech cancels IPO and goes for Record €411M Exit

UPDATE (10/04/2017): Symetis has decided to cancel its IPO following its acquisition by Boston Scientific in a €411M deal. The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac valve conditions. With its […]

March 20, 2017 - 2 minutesmins - By Melanie De Almeida

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two new Phase III studies in Alzheimer’s with its antibody candidate gantenerumab, initially developed by the German biotech giant MorphoSys. The trials are expected to begin later this year, but Roche […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 7 Mar 2017

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […]

March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Mar 2017

A New Transatlantic Partnership takes on Antibiotic Resistance

The Swiss biotech BioVersys and the US company Aptuit have entered a new collaboration to target antibiotic resistances. BioVersys, based in Basel, is developing small molecules that interfere with bacterial resistance mechanisms. Its current research is focused on nosocomial infections (hospital infections) and tuberculosis. To advance the development of compounds against novel targets identified by BioVersys, the company has […]

March 7, 2017 - 2 minutesmins - By Melanie De Almeida

AC Immune Genentech crenezumab phase III

News and Trends 28 Feb 2017

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up with Genentech to bring its amyloid beta (Aβ)-targeting antibody crenezumab into the clinic. Although the compound did not meet its co-primary enpoints in the large phase II ABBY trial, Genentech pushed […]

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

bidirectional neuroprosthesis university of geneva unige

More News! 24 Feb 2017

Interfacing the Brain & Machines: Another Step to a Cyborg Future

Controlling robotic prostheses with one’s mind has been a hot topic in research, but making a prothesis ‘talk back’ has been a stumbling block. Researchers from Switzerland show progress in creating sensations from a bidirectional neuroprosthesis. Researchers from the University of Geneva, in Switzerland, are developing a new method to connect a prosthesis to neural activity […]

February 24, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 15 Feb 2017

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […]

February 15, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 7 Feb 2017

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors has participated in Prexton Therapeutics’ latest financing round. The €29M Series B round was co-led by the Dutch Forbion and the Irish Seroba Life Sciences, […]

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 27 at 2.17.05 PM 1 e1485524200727

Startup Scout 27 Jan 2017

Needle-free Treatments for Autoimmune Disorders from Switzerland

It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases. City: Hergiswill, Switzerland Founded: 2014 Employees: 1-10 Financial data: N/A Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory […]

January 27, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

Swiss-Danish Collaboration will use Synbio to Produce a B Vitamin

Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster

Novartis puts the Development of two Anti-Aging Drugs in American Hands

UPDATE: Swiss Medtech cancels IPO and goes for Record €411M Exit

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

A New Transatlantic Partnership takes on Antibiotic Resistance

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

Interfacing the Brain & Machines: Another Step to a Cyborg Future

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Needle-free Treatments for Autoimmune Disorders from Switzerland

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!